Erasca & Revolution Medicines
2 shared events · Importance 3 · Last updated Jul 05, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molecular glues. The two companies are currently engaged in a high-stakes intellectual property dispute over their competing lead drug candidates.
Regulatory
Erasca: Erasca is the defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about its drug candidate ERAS-0015, patent infringement claims, and a patient death during clinical trials. This has led to a significant drop in its stock price and market capitalization.
Revolution Medicines: Revolution Medicines is the company that accused Erasca of patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, claiming improper comparisons to its own drug candidate RMC-6236. This action has negatively impacted Erasca.
May 19, 2026 · 189 articles
Regulatory
Erasca: Erasca is the defendant in a class action lawsuit alleging misleading statements regarding its ERAS-0015 drug candidate, which led to a drop in its stock price. The company denies the allegations and intends to contest them.
Revolution Medicines: Revolution Medicines (RevMed) is the company that alleged Erasca's ERAS-0015 infringes on its patent and involves trade secret misappropriation, initiating the legal dispute.
Jun 11, 2026 · 6 articles
90
Revolution Medicines sent letter alleging infringement ErascaErasca faces class action lawsuit
89
Revolution Medicines sent letter alleging infringement ErascaErasca Faces Securities...
76
Erasca disclosed letter Revolution MedicinesErasca Faces Securities...
NEWSDESK
Explore this relationship live
Track how Erasca and Revolution Medicines interact across events, view sentiment trends, and discover connected entities.
Open Dashboard